 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Companys M-001 universal influenza vaccine candidate. 